Goserelin न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

goserelin

teva pharma (new zealand) limited - goserelin acetate 4.1mg equivalent to 3.6 mg goserelin - subcutaneous implant - 3.6 mg - active: goserelin acetate 4.1mg equivalent to 3.6 mg goserelin excipient: polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation

ASTRZENECA GOSERELIN goserelin 10.8mg (as acetate) implant syringe ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

astrzeneca goserelin goserelin 10.8mg (as acetate) implant syringe

astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.

Zoladex 10,8, implantatiestaafje 10,8 mg नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zoladex 10,8, implantatiestaafje 10,8 mg

euro registratie collectief b.v. - goserelineacetaat samenstelling overeenkomend met; gosereline; - implantatietablet - goserelin

ZOLADEX- goserelin acetate implant संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

zoladex- goserelin acetate implant

a-s medication solutions - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

Zoladex-10,8, implantatiestaafje 10,8 mg नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zoladex-10,8, implantatiestaafje 10,8 mg

orifarm a/s energivej 15 5260 odense (denemarken) - goserelineacetaat samenstelling overeenkomend met ; ; gosereline - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Zoladex-3,6, implantatiestaafje 3,6 mg नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zoladex-3,6, implantatiestaafje 3,6 mg

orifarm a/s energivej 15 5260 odense (denemarken) - goserelineacetaat samenstelling overeenkomend met ; ; gosereline - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Zoladex 10,8 mg, implantatiestaafje नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zoladex 10,8 mg, implantatiestaafje

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 10,8 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Zoladex 3,6 mg, implantatiestaafje नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zoladex 3,6 mg, implantatiestaafje

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 3,6 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Zoladex-3,6, implantatiestaafje 3,6 mg नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zoladex-3,6, implantatiestaafje 3,6 mg

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 3,6 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

ZOLADEX- goserelin implant संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

zoladex- goserelin implant

tersera therapeutics llc - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl